Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Exclusion Criteria

• •You will not be eligible for this study if you:
• •Are diagnosed with hepatitis within 30 days prior to study entry.
• •Have certain serious medical conditions, including an AIDS-defining clinical condition.
• •Received chemotherapy or radiation therapy within 30 days of study entry.
• •Have taken any nucleoside reverse transcriptase inhibitors (NRTIs) for more than 2 weeks.
• •Have ever taken 3TC.
• •Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs).
• •Have taken medications that affect your immune system within 30 days prior to study entry.
• •Have received a vaccine within 30 days prior to study entry.
• •Are enrolled in another anti-HIV drug study while participating in this study.
• •Abuse alcohol or drugs.
• •Are pregnant or breast-feeding.